



ASO VISUAL ABSTRACT

# ASO Visual Abstract: Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases

Joy Sarkar, MD<sup>1</sup>, Kristopher Attwood, PhD<sup>2</sup>, and Roderich E. Schwarz, MD<sup>1</sup>

<sup>1</sup>Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY; <sup>2</sup>Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY

In a retrospective study of 43,039 patients with synchronous liver-only metastases from colorectal cancer (<https://doi.org/10.1245/s10434-023-14302-9>), receipt of perioperative chemotherapy with resection correlated with superior


overall survival (median 44.7 months). Additionally, superior overall survival was more closely linked to resection of the metastatic site than to resection of the primary tumor.

## Perioperative Chemotherapy Is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases

Sequence of localized and systemic treatment for colorectal liver metastases (CRLM) remains debated



National Cancer Database analysis:  
• 43,039 patients with liver-only CRLM  
• 8,678 patients underwent liver resection  
• Multivariate analysis



Perioperative chemotherapy + liver resection was associated with best median OS of 54.8 months vs 37.7 months for liver resection + postoperative chemotherapy



All patients with resectable CRLM deserve formal multimodality evaluation prior to finalizing treatment plan

Sarkar et al. *Ann Surg Oncol*.  
Visual Abstract for @AnnSurgOncol

ANNALS OF  
**SURGICAL ONCOLOGY**